Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker

Pediatric Nephrology

Volumn 23, Issue 2, 2008, Pages 333-334

  Celentano, Claudio ^a   Prefumo, Federico ^b   di Vera, Elena ^a   Iannicco, Annamaria ^a   Gallo, Davide Pio ^a   Liberati, Marco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute fetal renal failure; Drug safety; Prenatal diagnosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; FUROSEMIDE; METHYLDOPA; OLMESARTAN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FETOTOXICITY; FETUS; FETUS GROWTH; GESTATIONAL AGE; HUMAN; HYPERTENSION; INFANT; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MATERNAL TREATMENT; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOHYDRAMNIOS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RENOGRAPHY; SINGLE DRUG DOSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIURETICS; FEMALE; FETAL DISEASES; FUROSEMIDE; GESTATIONAL AGE; HUMANS; IMIDAZOLES; INFANT, NEWBORN; KIDNEY FAILURE; MALE; MATERNAL EXPOSURE; OLIGOHYDRAMNIOS; PREGNANCY; PRENATAL DIAGNOSIS; RECOVERY OF FUNCTION; TETRAZOLES; TREATMENT OUTCOME;

EID: 38349037667     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0618-8     Document Type: Article

References (12)

1. Cooke CE, Fatodu H (2006) Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm 12:649-655
2. Pryde PG, Sedman AB, Nugent CE, Barr M Jr (1993) Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3:1575-1582
3. Saji H, Yamanaka M, Hagiwara A, Ijiri R (2001) Losartan and fetal toxic effects. Lancet 357:363
4. Alwan S, Polifka JE, Friedman JM (2005) Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73:123-130
5. Daikha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R (2006) Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol 21:729-732
6. Quan A (2006) Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 82:23-28
7. Prandota J (2001) Clinical pharmacology of furosemide in children: A supplement. Am J Ther 8:275-289
8. Kelly TF, Moore TR, Brace RA (1993) Hemodynamic and fluid responses to furosemide infusion in the ovine fetus. Am J Obstet Gynecol 168:260-268
9. Flack NJ, Sepulveda W, Bower S, Fisk NM (1995) Acute maternal hydration in third-trimester oligohydramnios: Effects on amniotic fluid volume, uteroplacental perfusion, and fetal blood flow and urine output. Am J Obstet Gynecol 173:1186-1191
10. Iura T, Makinoda S, Fujita S, Matsuzawa S, Waseda T, Oshima K, Tomizawa H (2005) Analysis of the renal artery hemodynamics in normal fetuses using the color Doppler method. Fetal Diagn Ther 20:86-90
11. Barr M (1994) Teratogen update: Angiotensin-converting enzyme inhibitors. Teratology 50:399-409
12. Spence SG, Allen HL, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS (1995) Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 51:367-382